Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.43 |
| ▸ | NMBR | P28336 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31414641 | 0.89 | NMBR (0.46) | SIRT2NMBR | |
| SCHEMBL29427173 | 0.82 | MDM4 (0.46) | SIRT2NMBR | |
| SCHEMBL30882170 | 0.80 | SIRT2 (0.43) | SIRT2NMBR | |
| SCHEMBL30129799 | 0.79 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL31094878 | 0.78 | SIRT2 (0.41) | SIRT2NMBROPRD1 | |
| SCHEMBL29534108 | 0.78 | TDP1 (0.42) | SIRT2NMBR | |
| SCHEMBL30665993 | 0.78 | NMBR (0.44) | SIRT2NMBR | |
| SCHEMBL17859348 | 0.77 | SIRT2 (0.51) | SIRT2NMBR | |
| SCHEMBL7368138 | 0.77 | SIRT2 (0.51) | SIRT2NMBR | |
| SCHEMBL9959535 | 0.77 | SIRT2 (0.53) | SIRT2NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | VECTIVBIO AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2025-06-12 | — | — | US | disclosed |
| US-20250049893-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2025-02-13 | — | — | US | disclosed |
| US-20240325500-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2024-10-03 | — | — | US | disclosed |
| US-20240252595-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2024-08-01 | — | — | US | disclosed |
| US-11766470-B2 | Manufacture, formulation and dosing of apraglutide | VECTIVBIO AG (CH) | 2023-09-26 | — | — | US | disclosed |
| US-20230241179-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2023-08-03 | — | — | US | disclosed |
| US-20230173033-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4161553-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VectivBio AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241179-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-11766470-B2 | Manufacture, formulation and dosing of apraglutide | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-20240252595-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-20230173033-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-20250049893-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
| US-20240325500-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | SIRT2 202/4885NMBR 1577/4885OPRD1 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.